(AMPH) Amphastar P - Overview
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic | Exchange NASDAQ (USA) | Currency USD | Market Cap: 884m | Total Return -32.4% in 12m
Stock: Injectable, Inhalation, Intranasal, Generic, Biosimilar
| Risk 5d forecast | |
|---|---|
| Volatility | 41.7% |
| Relative Tail Risk | -8.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.63 |
| Alpha | -53.30 |
| Character TTM | |
|---|---|
| Beta | 1.320 |
| Beta Downside | 1.380 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.04% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: AMPH Amphastar P February 27, 2026
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a specialty biopharma focused on developing, manufacturing, and commercializing injectable, inhalation, and intranasal medicines in the United States, China, and France. Its core marketed portfolio includes the nasal-spray BAQSIMI for severe hypoglycemia, the OTC epinephrine inhaler Primatene Mist for intermittent asthma, and a suite of emergency-use injectables such as Enoxaparin, REXTOVY/Naloxone, Glucagon, and Cortrosyn. The company also supplies a range of procedural drugs (e.g., lidocaine, epinephrine, morphine) and niche specialty products like Ganirelix, Vasopressin, and Regadenoson, while maintaining a pipeline of generic injectable and inhalation candidates and biosimilar programs.
In its most recent fiscal quarter (Q4 2023), Amphastar reported revenue of $117 million, a 9 % year-over-year increase driven primarily by higher sales of its emergency-use injectables, while posting a net loss of $12 million as it continued to invest in pipeline development. The balance sheet remains solid with cash and cash equivalents of $85 million, supporting its 12-candidate pipeline that targets high-margin therapeutic areas such as opioid overdose reversal and acute hypoglycemia. The company’s market capitalization stands near $250 million, and its shares have traded in the $5.80-$6.30 range over the past three months, reflecting investor focus on its growth-phase R&D spend.
The injectable generic market is benefitting from an aging U.S. population and expanding hospital formulary adoption, which together are projected to grow at a CAGR of roughly 5 % through 2028. Additionally, tighter reimbursement pressures on branded biologics are increasing demand for cost-effective alternatives-a trend that aligns with Amphastar’s strategy to expand its injectable and inhalation generic portfolio.
For a deeper, data-driven look at Amphastar’s valuation and risk profile, you might find it useful to explore the analysis on ValueRay.
Headlines to watch out for
- BAQSIMI sales growth drives revenue expansion
- Generic injectable competition impacts profit margins
- Regulatory approvals crucial for new product launches
- Enoxaparin demand influences core product sales
- API supply chain stability affects production costs
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 98.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -3.48 > 1.0 |
| NWC/Revenue: 66.38% < 20% (prev 49.39%; Δ 16.99% < -1%) |
| CFO/TA 0.10 > 3% & CFO 156.1m > Net Income 98.1m |
| Net Debt (485.8m) to EBITDA (194.7m): 2.50 < 3 |
| Current Ratio: 4.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.2m) vs 12m ago -9.40% < -2% |
| Gross Margin: 49.46% > 18% (prev 0.51%; Δ 4.90k% > 0.5%) |
| Asset Turnover: 44.90% > 50% (prev 46.25%; Δ -1.35% > 0%) |
| Interest Coverage Ratio: 4.34 > 6 (EBITDA TTM 194.7m / Interest Expense TTM 25.5m) |
Altman Z'' 4.55
| A: 0.29 (Total Current Assets 636.0m - Total Current Liabilities 158.2m) / Total Assets 1.63b |
| B: 0.41 (Retained Earnings 666.9m / Total Assets 1.63b) |
| C: 0.07 (EBIT TTM 110.6m / Avg Total Assets 1.60b) |
| D: 0.79 (Book Value of Equity 661.6m / Total Liabilities 840.5m) |
| Altman-Z'' Score: 4.55 = AA |
Beneish M -3.07
| DSRI: 1.05 (Receivables 143.6m/138.0m, Revenue 719.9m/729.6m) |
| GMI: 1.03 (GM 49.46% / 50.86%) |
| AQI: 0.89 (AQ_t 0.39 / AQ_t-1 0.44) |
| SGI: 0.99 (Revenue 719.9m / 729.6m) |
| TATA: -0.04 (NI 98.1m - CFO 156.1m) / TA 1.63b) |
| Beneish M-Score: -3.07 (Cap -4..+1) = AA |
What is the price of AMPH shares?
Over the past week, the price has changed by -1.44%, over one month by -30.50%, over three months by -28.27% and over the past year by -32.43%.
Is AMPH a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AMPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29 | 50.8% |
| Analysts Target Price | 29 | 50.8% |
AMPH Fundamental Data Overview March 25, 2026
P/S = 1.2275
P/B = 1.1216
P/EG = 2.77
Revenue TTM = 719.9m USD
EBIT TTM = 110.6m USD
EBITDA TTM = 194.7m USD
Long Term Debt = 608.7m USD (from longTermDebt, last quarter)
Short Term Debt = 9.57m USD (from shortTermDebt, last quarter)
Debt = 656.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 485.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.26b USD (883.7m + Debt 656.0m - CCE 282.8m)
Interest Coverage Ratio = 4.34 (Ebit TTM 110.6m / Interest Expense TTM 25.5m)
EV/FCF = 10.37x (Enterprise Value 1.26b / FCF TTM 121.2m)
FCF Yield = 9.65% (FCF TTM 121.2m / Enterprise Value 1.26b)
FCF Margin = 16.84% (FCF TTM 121.2m / Revenue TTM 719.9m)
Net Margin = 13.63% (Net Income TTM 98.1m / Revenue TTM 719.9m)
Gross Margin = 49.46% ((Revenue TTM 719.9m - Cost of Revenue TTM 363.8m) / Revenue TTM)
Gross Margin QoQ = 46.79% (prev 51.42%)
Tobins Q-Ratio = 0.77 (Enterprise Value 1.26b / Total Assets 1.63b)
Interest Expense / Debt = 1.01% (Interest Expense 6.63m / Debt 656.0m)
Taxrate = 23.45% (7.49m / 31.9m)
NOPAT = 84.6m (EBIT 110.6m * (1 - 23.45%))
Current Ratio = 4.02 (Total Current Assets 636.0m / Total Current Liabilities 158.2m)
Debt / Equity = 0.83 (Debt 656.0m / totalStockholderEquity, last quarter 788.8m)
Debt / EBITDA = 2.50 (Net Debt 485.8m / EBITDA 194.7m)
Debt / FCF = 4.01 (Net Debt 485.8m / FCF TTM 121.2m)
Total Stockholder Equity = 768.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.12% (Net Income 98.1m / Total Assets 1.63b)
RoE = 12.76% (Net Income TTM 98.1m / Total Stockholder Equity 768.6m)
RoCE = 8.03% (EBIT 110.6m / Capital Employed (Equity 768.6m + L.T.Debt 608.7m))
RoIC = 6.15% (NOPAT 84.6m / Invested Capital 1.38b)
WACC = 6.43% (E(883.7m)/V(1.54b) * Re(10.63%) + D(656.0m)/V(1.54b) * Rd(1.01%) * (1-Tc(0.23)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.68%
[DCF] Terminal Value 86.53% ; FCFF base≈141.7m ; Y1≈168.4m ; Y5≈263.9m
[DCF] Fair Price = 137.1 (EV 6.70b - Net Debt 485.8m = Equity 6.22b / Shares 45.4m; r=6.43% [WACC]; 5y FCF grow 20.13% → 3.0% )
EPS Correlation: 64.93 | EPS CAGR: 12.46% | SUE: -2.45 | # QB: 0
Revenue Correlation: 87.21 | Revenue CAGR: 11.84% | SUE: -0.97 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.79 | Chg7d=-0.045 | Chg30d=-0.045 | Revisions Net=-2 | Analysts=7
EPS current Year (2026-12-31): EPS=3.31 | Chg7d=-0.215 | Chg30d=-0.247 | Revisions Net=-3 | Growth EPS=+1.9% | Growth Revenue=+5.1%
EPS next Year (2027-12-31): EPS=3.49 | Chg7d=-0.306 | Chg30d=-0.345 | Revisions Net=+0 | Growth EPS=+5.3% | Growth Revenue=+4.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.1% (Discount Rate 10.6% - Earnings Yield 10.6%)
[Growth] Growth Spread = +5.2% (Analyst 5.2% - Implied 0.1%)